Suppr超能文献

纤溶酶原激活系统在胃癌患者中的预后价值。

Prognostic value of the plasminogen activation system in patients with gastric carcinoma.

作者信息

Ganesh S, Sier C F, Heerding M M, van Krieken J H, Griffioen G, Welvaart K, van de Velde C J, Verheijen J H, Lamers C B, Verspaget H W

机构信息

Department of Gastroenterology and Hepatology, University Hospital, Leiden, The Netherlands.

出版信息

Cancer. 1996 Mar 15;77(6):1035-43. doi: 10.1002/(sici)1097-0142(19960315)77:6<1035::aid-cncr5>3.0.co;2-g.

Abstract

BACKGROUND

Patients with gastric cancer have a poor prognosis and can be cured by surgery only if the cancer is detected in an early stage. Extended surgery, down staging with chemotherapy before operation, and new postoperative treatments are recent approaches to increase survival rates. Categorizing patients' prognoses as good or poor by pathophysiologic markers, however, may be of great help in selecting therapies for these patients. For example, plasminogen activation (PA) parameters, that play an important role in tumor invasion and metastasis, have prognostic value for several human malignancies.

METHODS

We evaluated the relation between several PA parameters in tissue with standard clinicopathologic parameters and with the overall survival of 50 consecutive patients with gastric carcinoma.

RESULTS

Univariate analysis showed that a low tissue-type plasminogen activator (t-PA) activity in normal mucosa and in carcinomas and a high antigen level of inhibitor type-1 (PAI-1), and, to a lesser extent, of urokinase-type plasminogen activator (u-PA) receptor, in carcinomas are associated with a poor overall survival of the patients. In contrast, of the 14 clinicopathological parameters only the number of eosinophils in the tumors was associated with survival. Multivariate analysis revealed that the t-PA and PAI-1 levels are independently associated with survival.

CONCLUSIONS

Plasminogen activation parameters in both normal and carcinomatous tissue of the stomach of patients with gastric carcinoma are of particular clinical interest because of their prognostic impact on overall survival.

摘要

背景

胃癌患者预后较差,只有在癌症早期被检测到才能通过手术治愈。扩大手术范围、术前化疗降期以及新的术后治疗是提高生存率的最新方法。然而,通过病理生理标志物将患者的预后分为良好或不良,可能对为这些患者选择治疗方法有很大帮助。例如,在肿瘤侵袭和转移中起重要作用的纤溶酶原激活(PA)参数对几种人类恶性肿瘤具有预后价值。

方法

我们评估了组织中的几个PA参数与标准临床病理参数以及50例连续胃癌患者的总生存率之间的关系。

结果

单因素分析显示,正常黏膜和癌组织中低组织型纤溶酶原激活剂(t-PA)活性、癌组织中高1型抑制剂(PAI-1)抗原水平以及程度较轻的尿激酶型纤溶酶原激活剂(u-PA)受体与患者较差的总生存率相关。相比之下,在14个临床病理参数中,只有肿瘤中的嗜酸性粒细胞数量与生存率相关。多因素分析显示,t-PA和PAI-1水平与生存率独立相关。

结论

胃癌患者胃的正常组织和癌组织中的纤溶酶原激活参数因其对总生存率的预后影响而具有特殊的临床意义。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验